BMI View: While the UK government s immediate focus will be on negotiating favourable terms for trading and working with the EU after Brexit, the impact on health and social care will be a key topic of discussion. A slowdown in UK GDP growth and a drop in consumer demand does not necessarily signal a reduction in health spending, particularly as the government is committed to the NHS and a large number of patients will continue to purchase private healthcare services over the pressured public sector. ...BMI View: While the UK government s immediate focus will be on negotiating favourable terms for trading and working with the EU after Brexit, the impact on health and social care will be a key topic of discussion. A slowdown in UK GDP growth and a drop in consumer demand does not necessarily signal a reduction in health spending, particularly as the government is committed to the NHS and a large number of patients will continue to purchase private healthcare services over the pressured public sector. However, if an economic shock materialises and the government places financial pressures on the NHS, certain areas of the healthcare sector will suffer. ...A slowdown in UK GDP growth and a drop in consumer demand does not necessarily signal a reduction in health spending, particularly as the government is committed to the NHS and a large number of patients will continue to purchase private healthcare services over the pressured public sector. However, if an economic shock materialises and the government places financial pressures on the NHS, certain areas of the healthcare sector will suffer.
...BMI View: The UK government will remain focused on controlling pharmaceutical expenditure - continuing with initiatives and enforcing new measures to contain pharmaceutical spending growth. The country s decision to leave the EU and a slowdown in UK GDP growth may delay consultations or regulations that call for an increase in pharmaceutical expenditure, disappointing drugmakers that operate in an already challenging business environment. ...BMI View: The UK government will remain focused on controlling pharmaceutical expenditure - continuing with initiatives and enforcing new measures to contain pharmaceutical spending growth. The country s decision to leave the EU and a slowdown in UK GDP growth may delay consultations or regulations that call for an increase in pharmaceutical expenditure, disappointing drugmakers that operate in an already challenging business environment. Despite this, the UK will remain a top investment market for multinational drugmakers. ...Despite this, the UK will remain a top investment market for multinational drugmakers. The expanding, ageing population will continue to boost demand for healthcare and innovative pharmaceuticals.
...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...
...